U.S. markets closed

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.5200+0.0100 (+0.22%)
At close: 4:00PM EDT

4.5200 0.00 (0.00%)
After hours: 4:15PM EDT

Sign in to post a message.
  • G
    Gina
    I guess everyone had 5$ sell orders. That may prove to be regretful.
  • R
    ROBERT
    amazing run on no news! Any insights as to why? next stop $5?
  • s
    scot
    Up 30% in 5 days....and crickets on the message board... ODD...very ODD....
  • A
    ATM
    I expect smart money to drive PPS to $7.02 and market cap to $300M before preliminary trial data is released. No news is good news! I than expect preliminary data to be released shortly after $300M market cap and this stock like other Covid plays and Kodak should see at least 3-5x move in PPS. I expect a quick move towards $1B-$1.5B range on announcement of great data in keeping patience out of ICU and ventilator use.
  • S
    Savage
    easy money short 💰 🤑 💸
  • j
    john
    What is driving the volatility
  • A
    ATM
    Now, you might be saying why the 200+ % rise Since June 16? Well, the market cap was ridiculously low like around $60M and change with very low volume trading hands even with Covid announcement. So, other Covid plays took off and ACRS didn’t. Many of those Covid plays ran up on speculation In many cases to $1B or more than sell off followed like VBIV. These smart money traders we’re looking for another Covid play with very small market cap and ACRS was it. They since drove this market cap to $200M while its peers were 2x-4x this value. With a tiny 42.72M float and Nearly none of the big boys selling, smart money recognized growth potential and pounced on this stock.
  • A
    ATM
    Let me share with you what is going on. No news is good news with Aclaris as we approach day 60 of patient 1 treatment. It takes 60 days for them to gather SAEs. Given that no serious adverse events halted trial, trial must be moving along just fine. If a few patience that took ATI-450 required ventilators and died, trial would probably be halted for closer examination of data. None of this happened so assumption is trial is progressing just fine and preliminary results should be eminent so smart money is jumping on board to try and score at least 5x bounce on positive news that trial will be expanded at least they hope.
  • A
    ATM
    It’s all about float to public and market cap. Many Covid plays have market caps exceeding $500M and many cases approaching or exceeding $1B. ACRS could very easily approach these levels on speculation alone and get a big boost on trial expansion if ATI-450 tames CRS and reduces significantly number of Covid patience needing a ventilator in an ICU.
    Bullish
  • s
    scot
    That 8-K is HUGE....very impressive....
    Bullish
  • n
    nkov
    so glad I fastened my seatbelt!!!
  • K
    Kyle
    http://www.kumc.edu/news-listing-page/gan-polineni.html

    Just posted on 08/14/2020. I've been holding this stock for close to a year. Was impressed with pipeline and potential of company before any association to CoVid. Wondering other's thoughts on what a positive trial here could mean for the company, both short and long term.
    Physician-scientists Gregory Gan and Deepika Polineni pivoted from their research on cancer and cystic fibrosis to test a new drug with the potential to keep COVID-19 patients from needing a ventilator.
    Physician-scientists Gregory Gan and Deepika Polineni pivoted from their research on cancer and cystic fibrosis to test a new drug with the potential to keep COVID-19 patients from needing a ventilator.
    www.kumc.edu
  • V
    Villalobo
    I started following "awesomestokcalerts" (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • a
    aftab
    Upgraded to buy. Possibly $3 by noon tomorrow.
    Bullish
  • D
    Dorin
    7 or nothing
  • j
    john
    What and when is the next potential catalyst for this company?
  • j
    john
    What is driving the stock besides beta
    Bullish
  • G
    Greenberg
    BRUTAL Hot Rebound Play which is massive underpriced here trading wayyy below cash

    ACRS = Market Cap $43 M / Cash $115 M or untill end 2021 / 1 Marketed Product / 1 Phase 3 trial (common warts) with results expected in Q4 2019 and many other phase 2 programs / because of their strategic change they wants to out-license all their Prodcuts which means HUGE upfront payments forthe company (more infos below)= CHEAPEST Biotech you can get at this time

    Aclaris Therapeutics (ACRS)

    Market Cap: $43 M
    Cash: $115 M or enough untill end 2021

    Aclaris Therapeutics Announces New Strategic Direction
    https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-new-strategic-direction

    Pipeline
    https://www.aclaristx.com/pipeline/

    Largest Shareholders:

    Deerfield Management Company LP...5 893 416
    Franklin Advisers, Inc....3 953 203
    BlackRock Fund Advisors ...2 359 223
    Broadfin Capital LLC...2 280 260
    D. E. Shaw & Co. LP....2 049 462
    Sofinnova Ventures, Inc.....1 911 573
    Vivo Capital LLC ....1 647 214
    Fidelity Management & Research Co...1 562 190
    Polar Capital LLP...1 443 920
    The Vanguard Group, Inc...1 142 022
    The Investor Relations website contains information about Aclaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    The Investor Relations website contains information about Aclaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    investor.aclaristx.com
  • f
    frank
    I am long and so I don't care much for the S-T price movement, but it's not very convincing as to why the price continues to drop. ACRS has already one product called RHOFADE, approved by the U.S. Food and Drug Administration, or FDA, in January 2017 and started to create revenue through Allergan which distributes RHOFADE. They are also currently seeking a strategic partner to commercialize ESKATA, both in the United States and worldwide and indicated that this decision was due to the fact that revenues from product sales were insufficient for them to sustain continued commercialization as a result of the product not achieving sufficient market acceptance by physicians and patients, and not for efficacy or safety reasons. Thus, this product is not totally a failure. Finally, they have a strong pipeline which includes 1) recent announcement - a positive results from its Phase 3 clinical trial for an investigational new drug for the treatment of common warts, 2) total five phase 2 therapeutic indications currently undergoing plus various other programs. ACRS has a solid financial position for another 2 years while the products just developed started to bring more cash. Not sure why these potentials are overlooked.